Everywhere we go, it seems, people are talking about Exubera. They can’t seem to stop. Far more people, in fact, are chatting about the discontinued insulin inhaler than ever used the device. And given events, who can blame them?

After all, the bong turned out to be a colossal failure, the likes of which big pharma hasn’t experienced in, well, we’re not sure how long. After pumping up Wall Street with promises of $2 billion in annual revenue, sales were just $7 million this year. The little company that made Exubera was burned by not being told the game was over until the public announcement. Huge factories are now wasted investments. And then there’s that $2.8 billion charge.

But just how spectacular a flop is this debacle? Which image is best suited to convey the enormity of it all? Is it the inventive titanic failure designed by PharmaGossip? Or another dead zeppelin as envisioned by the imaginative PharmaGiles? Please share your feelings and vote here…

 Loading ...

Hat tip to PharmaGossip and PharmaGiles